The Psychedelic Therapeutics and Drug Development Conference
In this panel, field expert’s Dr Malcolm Barratt-Johnson and Graeme McFarlane will discuss the work of Albert Labs in utilising psilocybin as a means of treating cancer related anxiety, as well as their unique strategy for securing medical licensing through an adoption of Real-World Evidence based clinical trials.
-Bios:
Dr Malcolm Barratt-Johnson, Chief Medical Officer at Albert Labs: Malcom has over 22 years in the pharmaceutical industry specialising in Medical Affairs, Product Development and Regulatory Strategy. Malcom has worked extensively in senior positions to both Industry and Government. Holding positions at AstraZeneca, Roche, and the UK Medicines Regulatory Agency (MHRA) and European Medicines Evaluation Agency (EMEA). More recently Malcom, as a Clinical Specialist chaired the European Commission’s Biomedical Research Programme (Horizon 2020). He has also lectured in both Europe and the United States on Medicine & Drug Development.
Graeme McFarlane, Chief Commercial Officer at Albert Labs: 30+ years in the pharmaceutical industry holding senior management positions in Astra Zeneca, GlaxoSmithKline and Bristol Myers before starting two B2B companies specializing in Pharma Market Access, having brought in excess of 60 products to market in key areas of mental, cancer, and other national agenda diseases. A keen entrepreneur, Graeme enjoys growing start-up companies and has a special interest in new technologies that advance the improvement of healthcare delivery, unmet need and patient-centred solutions.
Albert Labs | http://albertlabs.com/
#Psychedelic #Medicine #Investing
--------
Interested to learn more?
1)First mover psychedelics company to leverage accelerated access to psilocybin based therapy in UK / Europe
2)The catalyst is a collaboration between academic research institutions, hospital centres and reimbursement networks
3)Blue Ocean strategy: addressing niche-mental health indications that can be quickly scaled without massive CapEx or competition among big pharma
4)Model is asset-light/risk mitigated, portable and can scale quickly while building IP
5)Accelerated access: The Albert Labs team are experts at conducting Real-World Evidence (RWE) studies that provide immediate patient enrollment in hospital settings
6)Albert Labs drives data collection & develops a revenue-generating psilocybin based medicine (KRN-101). Institutions get published opening up more access to funding, patients get solutions faster.
Learn more: https://albertlabs.com/
Subscribe for corporate news & investing opportunities.
In this panel, field expert’s Dr Malcolm Barratt-Johnson and Graeme McFarlane will discuss the work of Albert Labs in utilising psilocybin as a means of treating cancer related anxiety, as well as their unique strategy for securing medical licensing through an adoption of Real-World Evidence based clinical trials.
-Bios:
Dr Malcolm Barratt-Johnson, Chief Medical Officer at Albert Labs: Malcom has over 22 years in the pharmaceutical industry specialising in Medical Affairs, Product Development and Regulatory Strategy. Malcom has worked extensively in senior positions to both Industry and Government. Holding positions at AstraZeneca, Roche, and the UK Medicines Regulatory Agency (MHRA) and European Medicines Evaluation Agency (EMEA). More recently Malcom, as a Clinical Specialist chaired the European Commission’s Biomedical Research Programme (Horizon 2020). He has also lectured in both Europe and the United States on Medicine & Drug Development.
Graeme McFarlane, Chief Commercial Officer at Albert Labs: 30+ years in the pharmaceutical industry holding senior management positions in Astra Zeneca, GlaxoSmithKline and Bristol Myers before starting two B2B companies specializing in Pharma Market Access, having brought in excess of 60 products to market in key areas of mental, cancer, and other national agenda diseases. A keen entrepreneur, Graeme enjoys growing start-up companies and has a special interest in new technologies that advance the improvement of healthcare delivery, unmet need and patient-centred solutions.
Albert Labs | http://albertlabs.com/
#Psychedelic #Medicine #Investing
——–
Interested to learn more?
1)First mover psychedelics company to leverage accelerated access to psilocybin based therapy in UK / Europe
2)The catalyst is a collaboration between academic research institutions, hospital centres and reimbursement networks
3)Blue Ocean strategy: addressing niche-mental health indications that can be quickly scaled without massive CapEx or competition among big pharma
4)Model is asset-light/risk mitigated, portable and can scale quickly while building IP
5)Accelerated access: The Albert Labs team are experts at conducting Real-World Evidence (RWE) studies that provide immediate patient enrollment in hospital settings
6)Albert Labs drives data collection & develops a revenue-generating psilocybin based medicine (KRN-101). Institutions get published opening up more access to funding, patients get solutions faster.
Learn more: https://albertlabs.com/
Subscribe for corporate news & investing opportunities.
Comments